{"product_id":"luciasc-asciminib","title":"LuciAsc (Asciminib)","description":"\u003ch2\u003eAbout Asciminib\u003c\/h2\u003e\u003cp\u003eAsciminib is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).\u003csup id=\"cite_ref-Scemblix_FDA_label_5-1\" class=\"reference\"\u003e\u003c\/sup\u003e Asciminib is a protein kinase inhibitor.\u003csup id=\"cite_ref-Scemblix_FDA_label_5-2\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eChronic Myeloid Leukemia\u003c\/h3\u003e\u003ch4\u003eNewly diagnosed\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)\u003c\/li\u003e\n\u003cli\u003e80 mg PO daily OR 40 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue for as long as clinical benefit is observed or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003ePreviously treated\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in adults with previously treated Ph+ CML in CP\u003c\/li\u003e\n\u003cli\u003e80 mg PO daily OR 40 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue for as long as clinical benefit is observed or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eWith T315I mutation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in adults with Ph+ CML in CP with T315I mutation\u003c\/li\u003e\n\u003cli\u003e200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue for as long as clinical benefit is observed or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954326571,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0813.jpg?v=1787022223","url":"https:\/\/xomeds.com\/products\/luciasc-asciminib","provider":"XOMEDS","version":"1.0","type":"link"}